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1.	Introduction		Neuroplasticity	 is	 the	 remarkable	 anatomical	 and	 functional	 change	 of	 our	 brain	 that	allows	us	to	adapt	and	therefore	to	 learn	and	remember	new	things.	 It	 is	essential	 for	humans	from	infancy	when	we	start	reacting	to	our	outside	environment	until	later	in	life	 when	 we	 have	 to	 maximize	 our	 remaining	 capacity	 in	 order	 to	 adjust	 to	 the	continually	changing	environment.	Furthermore,	 it	 is	crucial	 for	recovery	after	central	nervous	system	(CNS)	injury	or	diseases	such	as	stroke	(Pascual-Leone	et	al.	2005)	or	multiple	 sclerosis	 (Ksiazek-Winiarek	 et	 al.	 2015).	 Maladaptive	 neuroplasticity	 on	 the	other	 hand	 is	 thought	 to	 be	 an	 underlying	 process	 in	 neurodegenerative	 and	neuropsychiatric	diseases	(Kolb	and	Gibb	2014).		So	how	does	neuroplasticity	work?		As	early	as	1949,	Hebb	stated	that	the	basis	of	 neuroplasticity	 lies	 within	 the	 synapses	 (Hebb	 1949).	 He	 studied	 how	 synaptic	connections	are	strengthened	when	they	are	activated	at	the	same	time.	Nowadays,	our	understanding	has	greatly	advanced	and	concepts	such	as	long-term	potentiation	(LTP)	and	 long-term	 depression	 (LTD)	 have	 been	 studied	 extensively.	 Proteins,	 genes	 and	other	 target	molecules	 which	 are	 supposed	 to	 play	 key	 roles	 in	 neuroplasticity	 have	been	found	(Malenka	and	Bear	2004).	Furthermore,	the	role	of	neuromodulators	such	as	dopamine,	which	primarily	do	not	 induce	plasticity	 themselves	but	can	 facilitate	or	inhibit	 it,	 has	 received	 increasing	 attention	 (Nitsche	 et	 al.	 2012).	They	 are	 thought	 to	exert	 a	 crucial	 role	 in	 the	 modulation	 of	 neuroplasticity	 and	 hence	 might	 control	learning	and	memory	formation.	Much	 of	 the	 research	 on	 neuroplasticity	 has	 been	 done	 in	 animal	 models.	However,	 new	 non-invasive	 brain	 stimulation	 techniques	 (NIBS)	 such	 as	 transcranial	magnetic	 stimulation	 (TMS)	 and	 transcranial	 direct	 current	 stimulation	 (tDCS)	 have	
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been	developed,	allowing	us	to	study	neuroplasticity	in	the	human	brain	and	hopefully	setting	 the	 groundwork	 for	 further	 research	 in	 understanding	 neuroplasticity	 more	thoroughly.	With	a	more	in	depth	understanding	of	neuroplasticity,	one	can	hope	to	find	therapeutic	 strategies	 to	 stimulate	plasticity	 in	 the	damaged	CNS.	 	This	would	greatly	advance	treatment	options	for	neurodegenerative	diseases	such	as	Alzheimer’s	disease,	which	 remain	 untreatable	 until	 now.	 This	 holds	 true	 also	 for	 other	 diseases	 that	 go	along	with	a	structural	change	or	altered	plasticity	 in	the	brain,	such	as	stroke,	MS,	or	even	depression	(Knable	et	al.	2002;	Floel	and	Cohen	2010;	Boggio	et	al.	2011;	Dimyan	and	Cohen	2011).			 In	 this	 thesis	 I	will	 first	elaborate	 the	concept	of	neuroplasticity	 in	general	and	then	 in	 the	 motor	 cortex.	 I	 will	 then	 introduce	 non-invasive	 brain	 stimulation	techniques	such	as	TMS	and	tDCS,	which	allow	us	to	induce	and	monitor	plasticity	in	the	human	 brain.	 Furthermore,	 I	 will	 give	 an	 overview	 of	 the	 role	 of	 dopamine	 in	neuroplasticity.	 Based	 on	 this	 background	 I	 define	 the	 aims	 and	 hypothesis	 of	 my	research:	the	investigation	of	the	effect	of	apomorphine,	a	global	dopamine	agonist,	on	motor	cortex	plasticity	in	humans,	which	I	will	then	present.				
1.1	Plasticity	in	the	Central	Nervous	System		Neuroplasticity,	the	ability	of	the	brain	to	reorganize	itself	structurally	and	functionally	in	 response	 to	 environmental	 changes,	 is	 thought	 to	 be	 the	 underlying	mechanism	of	learning	and	memory.	Plastic	changes	of	brain	structure	and	function	occur	on	a	variety	of	levels.				At	 the	 microscopic	 level,	 as	 Donald	 Hebb	 postulated,	 during	 the	 process	 of	learning,	 whenever	 	 pre-	 and	 postsynapses	 are	 activated	 simultaneously,	 a	 lasting	
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metabolic	 change	 and	 growth	process	 occurs	which	 leads	 to	 the	 strengthening	 of	 the	synapses	 involved	 (Hebb	 1949).	 Over	 the	 last	 50	 years	 our	 knowledge	 of	 those	metabolic	changes	and	growth	processes	has	greatly	advanced.	The	long	lasting	forms	of	synaptic	plasticity,	which	may	last	up	to	days	or	even	years,	pose	a	viable	model	for	learning	(Rioult-Pedotti	et	al.	2000)	and	long-term	memory	storage	(Citri	and	Malenka	2008).	LTP	and	LTD	have	been	thoroughly	studied,	especially	in	glutamatergic	synapses	in	 the	CA1	region	of	 the	hippocampus	 in	animals.	Binding	 to	 its	n-methyl-D-aspartate	(NMDA)	receptors	and	thus	activating	calcium	channels,	glutamate,	the	main	excitatory	neurotransmitter	 in	 the	 human	 brain,	 causes	 an	 increase	 in	 post-synaptic	 calcium	concentration	 and	 depending	 on	 the	 level	 of	 calcium	 influx	 either	 LTP	 (high	 calcium	influx)	 or	 LTD	 (low	 calcium	 influx)	 can	 be	 induced	 (Lisman	 2001).	 High	 calcium	concentration	 activate,	 among	 others,	 the	 calcium	 dependent	 kinase	 (CaMKII),	 which	leads	to	an	insertion	of		α-amino-3-hydrox-5-methyl-4-isoxazolepropionic	acid	(AMPA)	receptors	in	the	postmembrane	(Malinow	and	Malenka	2002).	A	low	calcium	influx,	on	the	 other	 hand,	which	 occurs	when	 the	 presynapses	 fire	 asynchronously	 or	with	 low	frequency,	 leads	 to	 an	 activation	 of	 the	 protein	 phosphatase	 1	 (PP1),	 which	 in	 turn	dephosphoralizes	and	 thus	 inactivates	 the	CaMKII,	 causing	a	decrease	 in	postsynaptic	AMPA	 receptors	 (D’	 Alcantara	 et	 al.	 2003).	 Between	 the	 thresholds	 of	 high	 or	 low	postsynaptic	calcium	concentration	that	either	triggers	LTP	or	LTD	respectively	exists	a	so	 called	 “no-man’s	 land”,	 which	 does	 not	 result	 in	 any	 plasticity	 changes	 (Lisman	2001).	Moreover,	 a	 very	 high	 calcium	 influx	 leads	 to	 an	 excitability	 reduction,	 as	 this	high	 increase	 in	 calcium	 results	 in	 a	 dephosphorylation	 and	 activation	 of	 potassium	channels,	which	then	causes	a	reduction	of	neuronal	activity	through	hyperpolarization	(Misonou	et	al.	2004).			
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Fig.1	Simplified	model	illustrating	the	induction	of	LTP	and	LTD.		Glutamate	release	of	the	pre-synapse	leads	to	an	increase	of	calcium	influx	in	the	postsynapse.	Depending	on	the	amount	of	calcium,	either	LTP	is	induced	(high	level	of	Ca2+	influx)	or	LTD	is	induced	(low	level	of	Calcium	influx).	(With	frienldy	permission	taken	from	Bear	and	Malenka	1994)	
 Despite	 the	knowledge	obtained	 so	 far,	we	 are	 still	 faced	with	many	questions	and	our	search	for	a	clear	physiologic	mechanism	behind	plasticity	goes	on	(Bliss	et	al.	2003).	Figure	1	shows	a	simplified	model	of	how	LTP	and	LTD	work	in	their	prototypic	form	of	a	glutamatergic	synapse	in	the	hippocampus:	not	only	the	intracellular	calcium	concentration	is	important	(Lisman	2001),	but	also	pre-	and	post	synapse	involvement	(Malenka	 and	 Bear	 2004),	 as	 well	 as	 the	 time	 point	 of	 activation	 (Citri	 and	Malenka	2008)	play	a	crucial	role.	The	model	of	spike	timing	dependent	plasticity	illustrates	that	whether	a	synapse	is	strengthened	or	weakened	changes	if	presynaptic	spike	arrival	is	milliseconds	before	or	after	postsynaptic	spikes	(Sjöström	and	Gerstner	2010).	In	some	synapses,	 LTP	does	 not	 depend	on	NMDA	 receptors	 but	 instead	 on	 kainate	 receptors	(Bliss	et	al.	2003)	and	gamma-aminobutyric	acid	 (GABA)	 interneurons	which	are	also	important	 for	 the	modulation	 of	 plasticity	 induction	 (Trepel	 and	Racine	 2000).	Much	more	 to	 the	 point	 however,	 a	 heterogeneous	 group	 of	 neurochemicals,	 known	 as	neuromodulators,	 also	 play	 a	 crucial	 role	 in	 modulating	 plasticity,	 especially	 in	 the	neocortex.	 One	 of	 the	 most	 intensely	 studied	 neuromodulator	 is	 dopamine	 as	 it	 is	
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Fig. 1. Model for the induction of LTP and LTD. During afferent activity, Ca2+ enters dendritic spines through NMDA receptors. During high- 
frequency stimulation (HFS), Ca2+ r aches high lev ls and prefere tially activates a protein kinase. During low-frequency stimulation (LFS), 
lower Ca2+ levels are achieved and this preferentially activates a protein phosphatase. Both the kinase and phosphatase act on a common 
synaptic phosphoprotein, the phosphorylation state of which controls synaptic strength. 
dentate gyrus in vivo 170,711 and in CA1 in vitro un- 
der special circumstances 1721. Bindman and colleagues 
173,741 recently have identified conditions in CA1 under 
which LTD of large magnitude may be elicited. Thus, in 
the presence of high concentrations of Mg*+ or excita- 
tory amino acid receptor antagonists to block synaptic 
transmission, either bursts of antidromic stimulation or 
intracellular depolarizing pulses yield a large depres- 
sion of the synaptic responses to orthodromic synaptic 
stimulation (upon wash-out of the high Mgz+ or antag- 
onist solution) 173,741. The effect was not observed in 
low extracellular Ca*+ suggesting that the underlying 
mechanism involves the entry of Ca*+ during condi- 
ti ning stimulation, as had been suggested previously 
1751. This approach may prove particularly useful for 
dissecting the mechanisms of LTD in locations such as 
the dentate gyrus, where heterosynaptic LTD is a ro- 
bust phenomenon in vivo, but has not been amenable 
to study in vitro 158’1. 
In 1989, a new form of LTD was described in CA1 [761. 
Evidence was presented that 5Hz single-pulse stimu- 
lation could produce a synaptic LTD in the stimulated 
pathway, but only if it was delivered out of phase 
with 100 Hz bursts (4 pulses) delivered at 5 Hz to a 
second pathway, or delivered conjointly with intra- 
cellular hyperpolarization 1771. This was termed ‘asso- 
ciative’ LTD. The finding was exciting because it con- 
firmed some theoretical predictions about how mem- 
ories might efficiently be stored in a network of hip- 
pocampal synapses 1781. These workers also showed 
that associative LTD was insensitive to the NMDA re- 
ceptor antagonist APV, but could be blocked by AI-‘3 
(2-amino-3-phosphonopropionate), which can block 
some of the biochemical effects of mGluR activation 
1791, again supporting a theoretical model of synap- 
tic plasticity 180,811. As Stevens 1821 put it, however, a 
‘silent controversy’ soon developed, with many labs ev- 
idently having difficulty in replicating associative LTD. 
Finally, in 1993, three groups published their indepen- 
dent findings that the associative stimulation protocol 
produces no LTD 183,841. 
Has associative LTD finally been laid to rest? Yes and 
no. The consensus is widespread that these associative 
conditioning protocols d  not produce LTD in CAl. 
However, in the dentate gyrus, Christie and Abraham 
1851 discovered a ‘priming’ procedure that allowed the 
expression of an associative LTD using out-of-phase 
stimulation of the medial and lateral perforant paths. 
Although similar priming failed to promote associative 
LTD in CA1 183,841, it is possible that some as-yet- 
undiscovered ‘preconditioning’ might facilitate asso- 
ciative LTD in CAl. In the meantime, we are forced to 
agree with the conclusion of Paulsen et al. 1831 that “a 
phenomenon as experimentally elusive as associative 
LTD is not likely to play a major ro e in hippocamp l 
function”. 
Homosynaptic LTD 
Dudek and Bear [86,871 recently introduced a new 
paradigm for the study of LTD in CAl. This has gener- 
ated excitement because the L’I’D can be observed in 
hippocampal slices under normal physiological condi- 
tions, has proven to be reproducible in other labs and 
appears to represent a reversal of the same mecha- 
nisms that produce LX? 
The basic observation is that several hundred stimuli 
delivered at low frequencies (l-3Hz) produce a sus- 
tained depression of modest but significant amplitude. 
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thought	to	play	an	important	role	in	learning	and	memory	formation.	Before	elaborating	on	the	role	of	dopamine	in	neuroplasticity	in	chapter	1.4,	motor	cortex	plasticity	will	be	explained	 in	 chapter	 1.2	 and	 the	 non-invasive	 brain	 stimulation	 tools	 TMS	 and	 tDCS,	which	allow	the	investigation	of	plasticity	in	humans,	will	be	explained	in	chapter	1.3.		
1.2	Motor	cortex	plasticity		Most	of	the	experimental	animal	and	in	vitro	LTP	/	LTD	studies	have	been	conducted	in	the	hippocampal	area	of	the	brain	or	with	cells	of	this	area,	because	the	hippocampus	plays	an	important	role	in	memory	formation	and	thus	glutamatergic	hippocampal	LTP	has	 become	 the	 prototype	 for	 synaptic	 plasticity	 (Citri	 and	Malenka	 2008).	 However,	this	area	would	not	be	easily	suitable	for	neuroplasticity	research	in	humans	as	it	is	not	easily	 accessible	 for	 direct	 study	 of	 neurophysiological	 mechanisms	 in	 humans	 via	electroencephalographic	 or	 non-invasive	 brain	 stimulation	 approaches	 because	 of	 its	distance	from	the	scalp	surface.	Alternatively,	the	primary	motor	cortex	(M1)	has	been	shown	 to	be	a	 suitable	 region	 for	examining	plasticity	as	 it	 is	 situated	at	 the	 cerebral	surface	 and	 thus	 accessible	 for	 non-invasive	 brain	 stimulation.	 Additionally,	 one	 can	obtain	objective	output	parameters	for	probing	induced	excitability	changes	indicative	of	 plasticity.	 Thirdly,	 the	 human	 motor	 cortex	 is	 well	 explored	 and	 plasticity	 of	 this	region	 has	 been	 thoroughly	 studied	 (Sanes	 and	Donoghue	 2000;	 Pascual-Leone	 et	 al.	2005).	 Much	 more	 to	 the	 point,	 the	 plasticity	 induced	 in	 the	 motor	 cortex	 shares	similarities	with	hippocampal	plasticity	as	motor	learning	and	cognition	are	also	based	on	 the	 principle	 of	 activity-driven	 synaptic	 strength	 changes	 (Sanes	 and	 Donoghue	2000).	Not	only	in	animal	studies	but	also	in	human	studies,	motor	cortex	plasticity	has	been	revealed	and	its	importance	for	recovery	after	damage	such	as	stroke	has	drawn	
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increasing	attention	to	this	field	(Hallett	2001).	The	somatotopic	representation	of	the	body	within	the	primary	motor	cortex	underlies	constant	reorganization	due	to	injuries	such	 as	 nerve	 lesion	 or	 limb	 amputation	 but	 also	 due	 to	 simple	 training,	 such	 as	repetition	of	basic	movements	(Classen	et	al.	1998;	Stefan	et	al.	2000).		It	is	thought	that	horizontal	inter-neurons	within	M1,	which	form	neuronal	assemblies	that	could	be	the	construct	 of	 such	 dynamic	motor	 representations,	 are	 the	 substrate	 for	M1	 plasticity	(for	a	review	see	(Sanes	and	Donoghue	2000)).			
 
1.3	Non-invasive	brain	stimulation		With	 the	 development	 of	 NIBS,	 a	 new	 field	 of	 research	 has	 emerged	 which	 includes	plasticity	 studies	within	 the	 human	 brain..	 Depending	 on	 the	 technique	 and	 protocol,	NIBS	 enable	 us	 to	 probe	 the	 excitability	 of	 the	 human	 brain	 through	 	 single	 pulse	transcranial	 magnetic	 stimulation	 (TMS)	 or	 they	 can	 induce	 plasticity	 (such	 as	 tDCS,	PAS,	repetitive	TMS).		The	 first	method	that	was	 invented	was	transcranial	electric	stimulation	(TES),	which	 uses	 high	 voltage	 current	 to	 induce	 action	 potentials	 (AP)	 of	 cortical	 neurons	under	 the	electrodes.	This	procedure	 is	however	painful	because	not	only	 the	cortical	neurons	are	activated,	but	also	nerve	endings	in	the	skin	and	head	muscles	and	thus	it	is	not	 well-suited	 for	 research	 purposes.	 Thereafter	 TMS	was	 introduced	 (Barker	 et	 al.	1985).	Working	with	a	strong	magnetic	pulse,	which,	after	penetrating	the	skull	induces	an	 electric	 field	 in	 the	 brain,	 TMS	 applied	 above	 the	 motor	 cortex	 in	 moderate	intensities	does	not	cause	pain	(Barker	et	al.	1985;	Rothwell	1993),	because	the	induced	current	does	not	 active	 the	pain	 fibre	nerve	 endings	 in	 the	 skin	or	 the	head	muscles.	Furthermore,	TMS	has	 the	advantage	over	TES	 that	magnetic	 stimulation	 is	diffuse	at	the	 surface	 and	 thus	 does	 not	 cause	 high	 current	 densities	 directly	 underneath	 the	
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stimulation	coil	(Barker	and	Freeston	2007).	Hence	TMS	became	popular	 for	research	and	since	its	discovery	an	innumerable	amount	of	studies	have	used	single	pulse	TMS-	elicited	motor	evoked	potentials	(MEP)	as	a	tool	to	monitor	or	repetitive	TMS	(rTMS),	patterned	rTMS	or	other	protocols	to	induce	plastic	changes.	RTMS	induces	frequency-specific	 after-effects,	with	 high	 frequency	 rTMS	 (≥5	Hz)	 increases	 and	 low	 frequency	rTMS	(≤1	Hz)	decreases	excitability	(Liew	et	al.	2014).		Other	techniques	that	induce	plasticity	within	the	human	cortex	are:	transcranial	direct-current	 stimulation	 (tDCS)	 and	 paired	 associative	 stimulation	 (PAS),	 etc.	 (for	 a	review	 (Vallence	 and	 Ridding	 2014)).	 As	we	 have	 used	 tDCS	 to	 induce	 plasticity	 and	single	pulse	TMS	to	monitor	those	changes,	both	techniques	will	be	explained	in	more	detail	 in	the	following	chapter.	PAS	combines	a	TMS	pulse	with	low-frequency	electric	suprathreshold	 peripheral	 nerve	 stimulation,	 which,	 depending	 on	 the	 interstimulus	interval	between	peripheral	and	TMS	pulse,	 induces	excitatory	or	inhibitory	plasticity.	PAS	after-effects	share	some	characteristics	with	those	of	tDCS,	as	they	are	also	NMDA	receptor	and	calcium	dependent	(Stefan	et	al.,	2002)	and	therefore	thought	to	be	LTP-	and	LTD-like.	Unlike	 tDCS,	which	 affects	 a	 big	 population	of	 neurons	under	 relatively	large	 stimulation	electrodes,	PAS	 is	 thought	 to	be	 focal	and	synapse-specific,	 affecting	only	small,	specific	population	of	neurons	(Stefan	et	al.	2002;	Classen	et	al.	2004).		
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Fig.	2	NIBS	schematic	chart	Chart	illustrating	different	TMS	and	tES	techniques	that	either	measure	(physiology)	or	induce	(neuromodulation)	neuroplasticity.	(With	friendly	permission	figure	taken	from	Liew	et	al.	2014).			
1.3.1 Single-pulse transcranial magnetic stimulation Single-pulse	 TMS	 is	 an	 approved	 technique	 to	 monitor	 corticospinal	 excitability	 and	quantify	 motor-cortical	 neuronal	 responses.	 It	 is	 based	 on	 the	 principle	 of	electromagnetic	 induction	 (Nahas	 2003).	 Generating	 a	magnetic	 field	 above	 the	 skull,	the	TMS	coil	induces	a	secondary	electrical	current	flow	in	the	cortical	area	underneath.	If	 the	 current	 is	 sufficiently	 large,	 the	 cortical	 neurons	 are	 depolarized.	 In	 the	motor	cortex	 this	 leads	 to	excitation	of	 corticospinal	projections	because	 the	cortical	neuron	activates	 the	 respective	 pyramidal	 tract	 neurons,	 which	 in	 turn	 causes	 a	 muscle	response	 (Di	 Lazzaro	 et	 al.	 1998).	 This	 can	 be	 recorded	 as	 motor	 evoked	 potential	(MEP)	 of	 the	muscle	 representing	 the	 stimulated	 cortical	 area.	 The	 amplitude	 of	 the	MEP	 represents	 corticospinal	 excitability.	 An	 increased	 excitability	 will	 result	 in	enhanced	MEP	 amplitudes	 and	 a	 decrease	 of	 excitability	 in	 reduced	MEP	 amplitudes	respectively.	 The	 muscle	 activities	 can	 be	 recorded	 using	 surface	 electromyography	electrodes	 and	 the	 size	 of	 the	 MEP	 amplitudes	 can	 be	 used	 to	 index	 the	 changes	 in	excitability	 before	 and	 after	 intervention	 with	 NIBS	 or	 pharmacological	 agents	(Rothwell	1993).	
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1.3.2 Transcranial direct current stimulation  Nitsche	 and	 Paulus	 (2000)	 have	 shown	 that	 transcranial	 direct	 current	 stimulation	(tDCS)	 is	 an	 eligible	 non-invasive	 method	 to	 modulate	 cortical	 excitability	 also	 in	humans.	 Animal	 experiments	 show	 that	 delivering	 weak	 subthreshold	 direct	 current	through	 two	 surface	 electrodes	 on	 the	 scalp	 does	 not	 induce	 an	 action	 potential,	 but	alters	the	membrane	resting	potential	of	the	affected	neurons,	and	consequently	alters	the	neuronal	excitability	and	spontaneous	neuronal	activity	(Nitsche	et	al.	2008).		So-called	 “anodal	 tDCS”	 over	 the	 motor	 cortex	 is	 attained	 by	 positioning	 the	anode	over	the	target	area	and	the	cathode	over	the	contralateral	orbit.	The	respective	current	flow	results	in	depolarizing	effects	on	membranes	of	cortical	neurons	and	thus	leads	to	an	increase	in	cortical	excitability.	Cathodal	tDCS	on	the	other	hand	works	vice	versa	 and	 hyperpolarizes	 the	 resting	 membrane	 potential,	 hence	 decreasing	 cortical	excitability.	Depending	on	the	stimulation	duration,	after-effects	can	be	induced	which	last	up	 to	60	minutes	 in	humans	when	 tDCS	 is	applied	 for	9-13	minutes	 (Nitsche	and	Paulus	2000;	Nitsche	and	Paulus	2001;	Nitsche	et	al.	2003a).	Furthermore,	it	was	shown	that	those	after-effects	are	abolished	by	NMDA	receptor	antagonists	(Fritsch	et	al.	2010,	Liebetanz	 et	 al.	 2002)	 and	 that	 they	 are	 calcium	 channel	 dependent	 (Nitsche	 et	 al.	2003b),	thus	suggesting	that	tDCS-induced	neuroplasticity	shares	common	mechanisms	with	 LTP	 and	 LTD	 (Vallence	 and	 Ridding	 2014).	 However,	 all	 underlying	 cortical	neurons	and	also	adjacent	cortical	areas	are	stimulated	nonspecifically,	so	the	effect	is	not	focal	(Figure	2).	The	larger	the	electrode,	the	less	focal	the	stimulation	(Nitsche	et	al.	2008),	 or	 vice	 versa,	 the	 smaller	 the	 stimulation	 electrode	 and	 bigger	 the	 reference	electrode,	 the	more	 focused	 is	 the	 tDCS-generated	modulation	 of	 cortical	 excitability	(Nitsche	 et	 al.	 2007).	 Furthermore,	 there	 is	 an	 inter-individual	 variation	 of	 tDCS-
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induced	current	flow	across	subjects	(Datta	et	al.	2012;	Wiethoff	et	al.	2014;	Strube	et	al.	2016).			 			
 
Fig	3.	Graphical	illustration	of	the	induced	cortical	surface	electric	field	(EF)	after	tDCS	The	graph	illustrates	that	tDCS-induced	after	effects	are	non-focal,	as	the	adjacent	cortical	areas	are	also	stimulated.	Figure	adapted	from	(with	friendly	permission	taken	from	Datta	et	al.	2012).		
 
	
1.4	Dopaminergic	modulation	of	neuroplasticity		In	 neurological	 and	 psychiatric	 disorders,	 most	 of	 our	 pharmacological	 treatment	options	influence	the	level	of	neurotransmitters	and	neuromodulators	in	the	brain.	For	instance	selective	serotonin	re-uptake	inhibitors	(SSRI),	a	widely	used	antidepressant-group,	 increase	 the	 level	of	serotonin	by	blocking	 its	uptake.	However,	even	though	 it	could	be	shown	that	psychiatric	medications	are	effective,	the	underlying	physiological	mechanisms	remain	often	unclear.	It	is	known,	though,	that	different	neurotransmitter	systems	 play	 different	 roles	 in	 the	 plasticity	 of	 the	 cortex.	 Whereas	 some	 of	 the	
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neurotransmitters	 such	 as	 glutamate	 and	 GABA	 can	 directly	 induce	 plasticity,	 other	neurotransmitters	 only	 have	 a	 modulatory	 impact,	 hence	 they	 are	 also	 called	neuromodulators.		This	means	that	they	can	induce	little	or	no	change	in	basal	neuronal	activity,	 but	 they	 can	 either	 potentiate	 or	 attenuate	 responses	 elicited	 by	 other	neurotransmitters	(Barchas	et	al.	1978).	They	do	this	either	by	changing	the	excitability	of	cortical	neurons,	by	alteration	of	the	signal	to	noise	ratio	of	neuronal	responses,	or	by	modulating	 the	 threshold	 of	 activity-dependent	 changes	 at	 the	 synapses	 (Gu	 2002).	How	they	influence	long-term	synaptic	changes	is	dependent	on	various	factors,	such	as	receptor	subtypes,	the	concentration	and	phasic	activity	of	the	modulators	and	the	site	of	action	(Nitsche	et	al.	2012).	Dopamine	 is	 one	 of	 the	 most	 thoroughly	 studied	 neuromodulators,	 as	 the	deregulation	 of	 the	 dopaminergic	 system	 is	 linked	 to	 many	 diseases,	 including	Parkinson’s	disease,	Tourette’s	 syndrome,	 schizophrenia,	 attention	deficit	 hyperactive	disorder	 (ADHD)	 and	 pituitary	 tumors	 (Vallone	 et	 al.	 2000).	 Furthermore,	 dopamine	agonists	 and	 antagonists	 are	 widely	 used	 as	 pharmacological	 treatment	 options	 for	Parkinson’s	disease	and	as	antipsychotic	medication	respectively.	Dopamine	also	plays	a	crucial	role	in	the	modulation	of	memory	formation	and	synaptic	plasticity	(Moal	and	Simon	 1991;	 Jay	 2003).	 Binding	 to	 specific	 presynaptic	 or	 postsynaptic	 membrane	receptors	 in	 many	 different	 areas	 of	 the	 brain,	 dopamine	 exerts	 its	 various	 actions.	There	are	 five	different	dopamine	receptors	 (DA-Rs),	D1	 to	D5,	all	of	which	belong	 to	the	group	of	G-protein-coupled	receptors.	They	can	be	roughly	divided	into	D1	and	D2	groups.	The	D1	group	consists	of	D1	and	D5	receptors.	The	receptors	are	Gs	receptors	and	thus	activate	the	adenylyl	cyclase	(AC),	which	stimulates	cAMP	formation	(Vallone	et	 al.	 2000;	Gu	2002),	 causing	 activation	of	protein	kinase	A	 (PKA).	PKA	exerts	many	different	functions,	among	others	the	stimulation	of	transcription	factors,	such	as	cAMP-
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responsive	element-binding	proteins	 (CREB),	modification	of	 synapses,	 and	control	of	ion	channels	(for	overview	see	Seamans	&	Yang	2004).			
  
Figure	4:	Schematic	representation	of	D1	group	receptors	signaling	pathway		Once	 dopamine	 binds	 on	 D1	 receptor,	 AC	 is	 activated,	 which	 leads	 to	 the	 formation	 of	 CAMP.	Consequently	PKA	is	activated,	which	in	turn	stimulates	CREB-dependent	gene	expression.	With	friendly	permission	taken	from	(Jay	2003).		
 The	 D2	 group	 consists	 of	 D2,	 D3	 and	 D4	 receptors	 and	 presynaptic	autoreceptors,	which	are	Gi	receptors	and	hence	inhibit	the	activation	of	AC.	Being	 one	 of	 the	 major	 neuromodulators	 in	 the	 brain,	 dopamine	 has	 been	extensively	 studied.	 It	 would	 be	 beyond	 the	 scope	 of	 this	 thesis	 to	 summarize	 all	dopamine-related	studies.	In	the	present	work	we	will	focus	on	studies	that	examine	the	dopaminergic	 modulation	 of	 neuroplasticity.	 Those	 studies	 can	 be	 divided	 into	 two	groups:	 plasticity	 studies	 in	 animals,	 which	 will	 be	 discussed	 in	 chapter	 1.4.1,	 and	plasticity	studies	in	humans,	which	will	be	presented	in	chapter	1.4.2		
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1.4.1.	Plasticity	studies	in	animals			The	role	of	dopamine	on	plasticity	is	complex,	because	on	the	one	hand	it	depends	on	the	receptor	subtype	that	is	activated	and	on	the	other	hand	it	varies	according	to	which	brain	region	is	involved.	Both	in	vitro	and	in	vivo	studies	examined	the	role	of	dopamine	on	 LTP	 and	 LTD	 in	 the	 hippocampus,	 the	 neocortex	 and	 the	 striatum	 (Jay	 2003).	Whether	D1	or	D2	receptors	are	activated	depends,	among	other	things,	on	the	level	of	dopamine	concentration.	Low	and	moderate	concentrations	of	dopamine	rather	activate	D1	 receptors	 and	 presynaptic	 D2	 autoreceptors,	 whereas	 high	 concentrations	 of	dopamine	also	activate	postsynaptic	D2	receptors	(Zheng	et	al.	1999).	Trying	 to	give	a	general	overview	of	 the	dopamine	 receptor	 functions,	one	 can	say	 that	 D1	 and	 D5	 receptor	 activation	 leads	 to	 an	 increase	 in	 plasticity.	 Lemon	 and	Manahan-Vaughan	(2006)	showed	that	by	stimulation	of	the	D1	receptor	subgroup	the	threshold	for	LTP,	as	well	as	LTD	induction,	is	lowered	(Lemon	and	Manahan-Vaughan	2006).	It	is	thought	that	this	process	is	regulated	through	cAMP-dependent	mechanisms	(Bailey	et	al.	2000;	Sajikumar	and	Frey	2004;	Tseng	and	O’Donnell	2004).		Other	studies	also	show	that	D1	receptor	activation	plays	an	important	role	in	LTP	(Otmakhova	and	Lisman	 1996;	 Bailey	 et	 al.	 2000;	 Gurden	 et	 al.	 2000;	 Centonze	 et	 al.	 2001;	 Kerr	 and	Wickens	 2001;	 Huang	 et	 al.	 2004;	 Hansen	 and	 Manahan-Vaughan	 2014)	 and	 LTD	induction	(Calabresi	et	al.	1992;	Chen	et	al.	1996;	Calabresi	et	al.	2000).	In	contrast,	D1	receptor	group	activation	can	also	completely	reverse	LTP	formation	into	LTD	(Mockett	et	al.	2007).		Activation	of	D2-receptor	results	 in	mixed	effects.	On	the	one	hand,	 it	has	been	reported	 that	 D2	 activation	 leads	 to	 an	 inhibition	 of	 LTD	 (Chen	 et	 al.	 1996)	 and	reduction	 of	 NMDA	 as	 well	 as	 GABAergic	 interneuron	 activation	 (Seamans	 and	 Yang	2004;	Tseng	and	O’Donnell	2004).	On	the	other	hand,	studies	have	shown	an	increase	in	
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LTP	 (Frey	 et	 al.	 1989;	 Manahan-Vaughan	 and	 Kulla	 2003;	 Abe	 et	 al.	 2008)	 and	 LTD	induction	(Otani	et	al.	1998;	Spencer	and	Murphy	2000;	Centonze	et	al.	2001;	Tang	et	al.	2001).			 In	order	to	explain	these	controversial	findings,	it	was	proposed	that	the	function	of	 dopamine	 on	 neuroplasticity	 does	 not	 only	 depend	 on	 receptor	 subtype	 and	 brain	region.	It	also	depends	on	the	timing	of	glutamate-dopamine	interaction	(Mockett	et	al.	2007)	and	on	duration	of	dopamine	receptor	stimulation,	as	well	as	on	concentration	level	 of	 dopamine	 (Seaman	 and	 Yang	 2004).	 For	 instance,	 some	 of	 the	 conflicting	findings	 of	 D1	 receptor	 group	 activation	 could	 be	 explained	 with	 the	 concept	 of	 a	inverted	U-shaped	dose	 response	profile	 of	D1	 activation,	meaning	 that	 low	and	high	levels	of	dopamine	inhibit	plasticity,	whereas	moderate	levels	increase	it	(Seamans	and	Yang	2004).	Furthermore,	the	focusing	concept	suggests	that	the	effect	of	dopaminergic	stimulation	 also	 depends	 on	 the	 level	 of	 cortical	 activity:	 high	 activity	 states	 will	 be	further	 enhanced	 through	 D1	 receptors	 (see	 also	 above),	 whereas	 D2	 receptor-mediated	reduction	of	cortical	activity	enhance	flexibility	of	cortical	activation	patterns.	This	 hypothesis	 is	 further	 supported	 by	 computational	 modeling	 (Durstewitz	 et	 al.	2000).	 Durstewitz	 and	 colleagues	 (2000)	 illustrated	 that	 if	 D1	 modulation	predominates,	 strong	 activity	 states	 benefit	 because	 D1	 activation	 enhances	 this	activity,	thus	allowing	a	stabilization	of	the	network	representation.		Furthermore,	they	propose	 that	 the	 underlying	 mechanism	 of	 how	 dopamine	 D1	 receptors	 stabilize	networks	is	by	an	increase	in	NMDA	and	a	reduction	in	AMPA	conductance.	Moreover,	by	 increasing	 GABAa	 conductance	 after	 stimulation	 of	 D1	 receptors,	 spontaneous	switches	to	other	states,	that	are	task-irrelevant,	are	prevented	(Durstewitz	et	al.	2000).	On	a	cognitive	level,	similar	findings	have	been	reported.	Cognitive	stability	is	increased	by	 rendering	 against	 interfering	 stimuli	 or	 noise,	 thus	 enhancing	 the	 signal	 to	 noise	
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ratio.	D1	activation	leads	to	a	prioritizing	of	information	storage	(Hansen	and	Manahan-Vaughan	 2014).	 For	 instance,	 tasks	 that	 require	 an	 early	 stabilization	 of	 a	 constant	neuronal	activation	circuit,	such	as	simple	reaction	time	task,	are	enhanced	through	D1	stimulation.	D2-dominated	states	on	the	other	hand	are	beneficial	for	tasks	that	require	high	 flexibility	 in	 choosing	 between	 different	 low	 activity	 states.	 D2	 receptor	stimulation,	 contrary	 to	 D1,	 leads	 to	 a	 reduction	 in	 NMDA	 receptor	 activity	 and	 LTP	formation,	 which	 in	 turn	 leads	 to	 a	 defocusing	 effect	 of	 the	 neuronal	 circuit.	Furthermore,	 GABAergic	 currents	 are	 inhibited,	 thus	 allowing	 to	 alternate	 between	different	neuronal	circuits	(Cools	and	D’Esposito	2011).		Summing	up,	the	focusing	concept	suggests	that	low	but	still	effective	dosages	of	dopamine	 activate	 D1	 receptors	 and	 thus	 increase	 highly	 active	 networks,	 allowing	them	to	pursue	a	goal	by	stabilizing	the	network	and	 thus	decreasing	the	 influence	of	distractors.	High	or	very	low	concentrations	of	dopamine	rather	activate	D2	receptors	and	 increase	performance	 in	 tasks	 that	 require	 a	 high	 flexibility	 by	 allowing	multiple	representations	of	different	low	activity	states.			
1.4.2	Plasticity	studies	in	humans			The	effects	of	dopamine	on	plasticity	in	humans	have	also	been	explored.	Two	studies	examined	 the	 effect	 of	 different	 levels	 of	 l-3,4-dihydroxyphenylalanine	 (L-dopa)	 on	human	 motor	 cortex	 plasticity.	 They	 demonstrated	 a	 non-linear	 dosage-dependent	effect	 of	 dopamine	 for	both	 facilitatory	 and	 inhibitory	plasticity,	 as	 both	 low	 (25	mg)	and	high	doses	 (200	mg)	 of	 L-dopa	 impaired	PAS-	 and	 tDCS-induced	plasticity,	while	under	medium	(100	mg)	dosage	preserved	and	even	prolonged	 the	plasticity	 induced	by	PAS	 and	 cathodal	 tDCS.	 anodal	 tDCS-induced	 LTP-like	 plasticity	was	 reversed	 into	
16		
	
inhibition	(Monte-Silva	et	al.	2010;	Thirugnanasambandam	et	al.	2011).	Another	study	testing	the	effect	of	100	mg	L-dopa	on	motor	cortex	plasticity	also	reports	that	the	focal	PAS-induced	 plasticity	 is	 prolonged	 by	 dopamine,	 whereas	 non-focal	 anodal	 tDCS	 no	longer	 increased	 and	 even	 reduced	motor	 cortex	 excitability	 in	 the	 L-dopa	 condition.	These	results	of	global	phasic	dopamine	effect	are	in	line	with	the	focusing	hypothesis	of	dopamine	(Kuo	et	al.	2008).		Different	dosages	(2.5,	10	and	20	mg)	of	bromocriptine,	a	selective	D2	receptor	agonist,	combined	with	tDCS	and	PAS	prevented	plasticity	alterations	 in	all	conditions	for	anodal	tDCS,	and	in	low	and	high	dosages	for	cathodal	tDCS	and	both	PAS	conditions.	Medium	 dosages	 on	 the	 other	 hand	 preserved	 plasticity	 induced	 by	 cathodal	 tDCS,	inhibitory	and	to	a	lesser	degree	facilitory	PAS,	and	thus	also	revealed	a	dose-dependent	modulation	 for	 D2	 receptors	 (Fresnoza	 et	 al.	 2014a).	 In	 contrast,	 blocking	 the	 D2	receptor	with	sulpiride	 (SULP)	resulted	 in	abolishment	of	 iPAS,	as	well	as	anodal	and	cathodal	tDCS	elicited	after-effects	(Nitsche	et	al.	2006;	Nitsche	et	al.	2009).	Similar	to	that,	neuroplasticity	elicited	by	theta-burst	stimulation	(TBS),	a	specific	rTMS	protocol,	was	also	impaired	by	SULP	(Monte-Silva	et	al.	2011).		To	study	the	influence	of	D1	receptors	on	human	motor	cortex	plasticity	is	more	challenging,	as	there	are	no	selective	agonists	or	antagonists	applicable	for	human	use.	Hence,	 the	relative	D1	receptor	contribution	can	only	be	tested	indirectly,	by	blocking	D2	 receptors	 and	 increasing	 the	 activity	 of	 D1	 receptor	 by	 applying	 either	 L-dopa	(Nitsche	 et	 al.	 2009;	 Fresnoza	 et	 al.	 2014b)	 or	 pergolide	 (Nitsche	 et	 al.	 2006).	Combining	 100	 mg	 of	 L-dopa	 with	 the	 D2	 blocker	 sulpiride	 preserved	 the	 plasticity	induced	by		PAS	and	tDCS,	showing	that	D1	receptor	activation	is	relevant	for	plasticity	induction	 in	 the	 human	motor	 cortex	 (Nitsche	 et	 al.	 2009).	 Combining	 sulpride	with	three	 different	 dosages	 of	 L-dopa	 (25,	 100	 and	 200	 mg)	 revealed	 a	 dose-dependent	
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modulation	 for	 D1	 receptor	 activation	 (Fresnoza	 et	 al.	 2014b).	 An	 inverted	 U-shape	effect,	meaning	 that	 only	medium	dosages	 (100	mg	L-dopa)	 lead	 to	 a	preservation	 in	plasticity	was	observed	 for	anodal	 tDCS,	cathodal	 tDCS,	and	excitatory	PAS.	Activating	the	D1	receptor	by	pergolide,	which	has	a	relatively	 low	affinity	 to	D1	receptors,	plus	sulpiride	reduced	the	after-effects	of	tDCS	(Nitsche	et	al.	2006).		Summarizing	the	findings	of	plasticity	studies	in	humans:	one	can	say	that	global	phasic	 dopaminergic	 activation	 in	medium	 dosage	with	 L-dopa	 (100	mg)	 leads	 to	 an	increase	 in	 inhibitory	plasticity,	reverses	non-focal	excitatory	 into	 inhibitory	plasticity	and	 strengthens	 focal	 facilitatory	 plasticity.	 Similar	 results	 have	 been	 observed	 with	medium	dosages	of	tonic	D2	receptor	activation	with	bromocriptine	(10	mg).	However,	D1	 receptor	 activation	 increases	 excitatory	 plasticity	 regardless	 of	 focality	 and	decreases	 inhibitory	 plasticity.	 The	 inverted	 U-shaped	 effect,	 meaning	 that	 medium	dosages	enhance	or	preserve	plasticity,	whereas	high	and	low	doses	abolish	plasticity,	was	 observed	 for	 global	 dopamine	 activation,	 as	 well	 as	 for	 D1,	 D2	 and	 D2	 and	 D3	receptor	 activation	 (Monte-Silva	 et	 al.	 2009;	 Monte-Silva	 et	 al.	 2010;	Thirugnanasambandam	et	al.	2011;	Fresnoza	et	al.	2014a;	Fresnoza	et	al.	2014b).			
	
1.4.3	Cognitive	studies	in	humans			It	 is	also	 thought	 that	dopamine	plays	an	 important	role	 in	neuroplasticity	 in	humans	and	hence	in	learning	and	memory	formation.	In	line	with	that,	studies	testing	learning	and	memory	 have	 shown	 an	 enhancing	 effect	 of	 dopamine.	 For	 instance,	 increase	 of	global	 dopamine	 level	with	 100	mg	 of	 levodopa	 in	 healthy	 subjects	 during	 repetitive	training	 improved	 word	 learning	 (Knecht	 et	 al.	 2004),	 increased	 motor	 memory	formation	 in	 healthy	 young	 subjects,	 and	 restored	 the	 capability	 to	 form	 a	 motor	
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memory	 in	elderly	 subjects	 (Flöel	et	al.	2005).	A	beneficial	effect	of	 learning	was	also	reported	 in	 acute	 and	 chronic	 stroke	 patients	 (Scheidtmann	 et	 al.	 2001;	 Floel	 et	 al.	2005;	Rösser	et	al.	2008).	However,	like		in	animal	studies,	in	human	studies	there	has	been	 found	 contrasting	 data	 in	 regard	 to	 the	 effect	 of	 dopamine	 receptor	 subtype	stimulation.	 In	 line	with	 the	 focusing	 theory	 developed	 in	 animal	 studies,	 Costa	 et	 al.	(2014)	showed	in	human	cognition	studies	that	there	is	a	focusing	effect	as	well,	which	can	explain	the	contrasting	data.		In	this	study	task	performances	that	require	cognitive	stability,	 like	 simple	 repetitive	 tasks,	 are	 facilitated	 by	 tonic	 D1	 activation,	 whereas	tasks	 that	 require	 cognitive	 flexibility	 allowing	 new	 mental	 representations	 benefit	from	phasic	D2	activation	(Costa	et	al.	2014).		
 
1.5	Apomorphine			Being	 a	 nonselective	 dopaminergic	 receptor	 agonist,	 apomorphine	 binds	 to	 all	dopamine	 receptors.	 The	 binding	 affinity	 (K)	 to	D1,	D2,	D3,	D4	 and	D5	 receptors	 are	101,	32,	26,	2.6	and	10	nM	respectively	(Vallone	et	al.	2000;	Hsieh	et	al.	2004).			 The	 pharmaco-therapeutic	 use	 of	 apomorphine	 has	 been	 quite	widespread.	 Its	main	 use	 is	 in	 the	 treatment	 of	 Parkinson’s	 disease	 and	 has	 already	 been	 studied	 in	1951	 (Schwab	et	 al.	 1951).	As	 it	 is	 as	well	 a	 strong	emetic,	 it	 should	always	be	given	together	 with	 antiemetic	 substances	 like	 domperidon.	 In	 Parkinsonian	 patients	apomorphine	 has	 shown	 to	 be	 able	 to	 reverse	motor	 cortical	 inhibition,	 suggesting	 it	can	modify	cortical	excitability	(Pierantozzi	et	al.	2001).			
1.6	The	aim	of	this	study	
 Considering	 the	 important	 role	 of	 dopamine	 in	 many	 diseases	 and	 also	 in	neuroplasticity,	 the	aim	of	 this	project	was	 to	 further	explore	 the	role	of	dopamine	 in	
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neuroplasticity.	 In	more	detail,	 this	 thesis	aims	 to	examine	 the	 influence	of	 the	global	dopamine	 agonist	 apomorphine	 on	 non-focal	 anodal	 tDCS-induced	 plasticity.	 The	commonly	 applied	 global	 dopamine	 agonist	 L-dopa	 is	 being	 metabolized	 to	norepinephrine,	 and	hence	 the	effects	of	 L-dopa	 cannot	be	 solely	be	 attributed	 to	 the	dopaminergic	 system.	Whereas,	 by	using	 apomorphine	only	 the	dopaminergic	 system	will	be	stimulated.	Another	problem	with	L-dopa	is,	that	its	effects	are	phasic,	whereas	the	 effects	 of	 agonists	 are	 tonic,	 meaning	 that	 the	 agonist	 binds	 to	 its	 receptor	independent	of	cortical	activity.	Thus,	different	effects	of	L-dopa	compared	to	agonists	might	be	caused	not	only	by	activation	of	different	receptor	subtypes	but	also	by	phasic-tonic	effects.	 Since	apomorphine	solves	 this	problem	as	an	agonist,	 it	 can	answer	 this	question.	Nevertheless,	it	is	hypothesized	that	the	effect	of	apomorphine	is	similar	to	L-dopa,	in	that	low	and	high	dosages	of	apomorphine	abolish	plasticity,	whereas	medium	dosages	 reverse	 non-focal	 excitatory	 plasticity,	 as	 induced	 by	 anodal	 tDCS,	 into	inhibitory	plasticity.		
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2.	Material	and	Methods	
2.1	Subjects	and	eligibility	criteria		12	 right-handed	 healthy	 subjects	 participated	 in	 the	 experiment	 (eight	 males,	 four	females,	age	25.75	±	3,54	years	(mean	±	SD).	Having	been	thoroughly	 informed	about	the	study,	 including	 the	methods	of	TMS	and	tDCS,	apomorphine	and	 its	possible	side	effects,	 each	 subject	 underwent	 a	 medical	 examination,	 and	 gave	 written	 informed	consent.	Exclusion	criteria	were	the	following:		1. Cardiac	pacemaker	or	a	deep	brain	stimulator	2. Intracerebral	metal	implants		3. Age	<	18	or	>	40		4. History	of	epileptic	seizures	5. History	of	craniocerebral	injury	with	loss	of	consciousness		6. History	of	an	acute	or	any	chronic	medical	disease		7. Legal	supervision		8. Present	pregnancy	or	lactation	period	9. Alcohol,	medical	or	drug	dependence	as	well	as	any	recreational	drug	use	10. 	Aphasia	11. 	Intake	of	medication	that	effects	the	central	nervous	system.	Alcohol	intake	was	not	 allowed	 one	 day	 before	 the	 experiment	 and	 on	 the	 day	 of	 the	 experiment	coffee	was	not	permitted.	12. 	Participation	in	a	drug	or	medical	device	study	8	weeks	prior	to	the	experiment	The	Ethics	Committee	of	the	University	of	Göttingen	approved	the	study	(5/7/09).					
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2.2	Monitoring	corticospinal	excitability	with	TMS		In	 this	 experiment	 we	 recorded	 the	 MEP	 of	 the	 right	 abductor	 digiti	 minimi	 muscle	(ADM)	 with	 single-pulse	 TMS,	 which	 was	 generated	 by	 a	 Magstim	 200	 magnetic	stimulator	(Magstim	Inc.,	Dyfed,	UK)	through	a	figure-eight	shaped	coil	(diameter	of	one	winding	 70	 mm;	 peak	 magnetic	 field	 2,2	 tesla)	 at	 a	 frequency	 of	 0.25	 Hz	 with	 5%	variation	 to	 avoid	 expectancy	 effects.	 In	 order	 to	determine	 the	optimal	 coil	 position,	the	coil	was	moved	slowly	above	the	scalp	holding	it	tangentially	to	the	scalp	at	an	45	°	angle	 to	 the	midsagittal	 plane	with	 the	 handle	 pointing	 posteriorly	 and	 laterally.	 The	site	where	stimulation	resulted	 in	 the	most	consistent	and	 the	 largest	MEP	amplitude	(hotspot),	 was	 marked	 with	 a	 skin-marker.	 Then	 the	 TMS	 intensity	 was	 adjusted	 to	elicit	baseline	(bl)	MEPs	of	averaged	1	mV.	The	MEPs	were	recorded	from	the	right	ADM	with	 surface	 electromyography	 (EMG)	 Ag-AgCl	 electrodes	 attached	 in	 a	 belly-tendon	montage.	The	signals	were	filtered	(30	Hz	to	2kHz),	amplified	(Digitimer	360,	Digitimer	Ltd,	Welweyn	Garden	City,	Herts,	UK)	and	then	stored	on	a	computer	via	a	Power	1401	data	 acquisition	 interface	 (Cambridge	 Electronic	 Design	 Ltd,	 Cambridge,	 UK).	 The	analysis	was	carried	out	with	Signal	Software	(Cambridge	Electronic	Design).		
 
2.3	Plasticity	induction	by	tDCS	
 In	 this	 study	 anodal	 tDCS	 was	 applied	 using	 a	 battery-driven	 constant	 current	stimulator	(NeuroConn)	with	a	maximum	output	of	4.5	mA.		A	current	strength	of	1	mA	was	 administered	 for	 13	 minutes,	 as	 previous	 studies	 have	 shown	 that	 13	 minutes	anodal	 stimulation	 is	 sufficient	 to	 induce	 cortical	 excitability	 alterations	 for	 about	 1	hour.	The	current	was	delivered	through	two	saline-soaked	surface	sponge	electrodes	each	 measuring	 7	 x	 5	 cm.	 The	 anode	 was	 positioned	 over	 the	 motor	 cortex	
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representation	area	of	the	right	ADM,	and	the	cathode	return	electrode	above	the	right	supraorbital	area.		
 
2.4	Medication	with	apomorphine		The	participants	received	either	low	(0.1	mg),	middle	(0.2	mg)	or	high	(0.3	mg)	dosage	of	 apomorphine	 or	 placebo	 via	 subcutaneous	 application	 ten	 minutes	 before	 the	plasticity-	inducing	protocol.	Approximately	at	this	time	point	apomorphine	reaches	its	highest	 plasma	 concentration	 (LeWitt	 2004).	 We	 chose	 0.3	 mg	 apomorphine	 as	 the	maximum	 dosage	 to	 avoid	 frequent	 systemic	 side	 effects.	 In	 order	 to	 minimize	peripheral	apomorphine	side	effects	such	as	a	decrease	in	blood	pressure,	nausea	and	vomiting	the	subjects	received	20	mg	of	the	peripheral	acting	dopaminergic	antagonist	domperidon	three	times	per	day	two	days	before	the	experiment	and	two	hours	before	apomorphine	 application.	 Grundey	 et	 al.	 (2013)	 have	 shown	 in	 a	 control	 experiment	that	20	mg	domperidon	alone	exerts	no	effect	upon	motor	cortex	excitability,	thus	does	not	interfere	with	the	experiment.		
	 	
2.5	Experimental	procedure		
 This	 study	 was	 conducted	 in	 a	 double-blinded,	 randomized	 and	 placebo-controlled	design.	Each	 subject	participated	 in	4	 sessions	 and	 each	 session	was	 separated	by	 an	interval	of	≥	1	week	to	avoid	cumulative	drug	and	stimulation	effects.		At	 the	beginning	of	 the	experiment	 the	 subject	was	 seated	on	a	 reclining	 chair	with	head	and	arm	support	and	was	asked	to	relax	and	to	keep	the	eyes	open	during	the	complete	course	of	 the	experiment.	Then	the	EMG	electrodes	were	placed	at	 the	right	
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ADM	and	the	motor	cortex	representation	area	of	that	muscle	was	determined	by	TMS.	Both	spots	were	marked	with	a	skin	marker	to	ensure	constant	positioning	of	the	coil	and	 electrodes	 throughout	 the	 session.	 Having	 identified	 the	 intensity	 of	 the	 TMS	stimulus	 that	 resulted	 in	MEPs	with	peak-to-peak	amplitudes	of	on	average	1	mV,	we	then	started	to	measure	the	first	baseline,	which	consisted	of	25	MEP.	Immediately	after	the	 baseline	measurements,	 the	 participants	 received	 either	 the	 apomorphine	 or	 the	placebo	(saline)	injection.	Ten	minutes	later	a	second	baseline	was	measured,	to	control	for	 possible	 drug-induced	 changes	 of	 MEP	 amplitudes.	 If	 baseline	 2	 differed	 from	baseline	1	(<0.2	mV	or	>0.2	mV),	TMS	intensity	was	adjusted	and	a	third	baseline	was	measured.	 Then	 anodal	 tDCS	was	 applied	 for	 13	minutes.	 Thereafter,	 25	MEPS	were	recorded	every	5	minutes	for	half	an	hour,	then	every	30	minutes	for	2	hours,	and	then	again	on	the	same	evening,	the	next	morning,	the	next	afternoon	and	the	next	evening	(Fig.	1).		
 
Premedication	 Medication	 Postmedication	 Plasticity	
Induction	
Monitoring	motor	cortex	excitability	
					BL	1	 	Placebo	 							BL	2	 	BL	3	 	Anodal	tDCS	 MEPs	every	5	min	for	30	min,	then	every	30	min	until	2	hours,	SE,	NM,	NA,	NE	after	intervention		
					BL	1	 	0.1	mg	apomorphine	 							BL	2	 	BL	3	 	Anodal	tDCS	 MEPs	every	5	min	for	30	min,	then	every	30	min	until	2	hours,	SE,	NM,	NA,	NE	after	intervention	
					BL	1	 	0.2	mg	apomorphine	 							BL	2	 	BL	3	 	Anodal	tDCS	 MEPs	every	5	min	for	30	min,	then	every	30	min	until	2	hours,	SE,	NM,	NA,	NE	after	intervention	
					BL	1	 	0.3	mg	apomorphine	 							BL	2	 	BL	3	 	Anodal	tDCS	 MEPs	every	5	min	for	30	min,	then	every	30	min	until	2	hours,	SE,	NM,	NA,	NE	after	intervention						
Figure	5.	Experimental	course	of	the	study		MEPs	elicited	by	single-pulse	TMS	over	the	left	motor	cortical	representation	area	of	the	right	ADM	were	recorded	at	1	mV	intensity	before	 drug	 application	 (baseline	 1	 (BL1)).	 8	minutes	 afterwards	 a	 second	 baseline	 (BL2)	was	 recorded	 to	 check	 for	 a	 possible	influence	 of	 the	 drug	 and	 adjusted	 if	 necessary	 (baseline	 3(BL3)).	 Then	 anodal	 tDCS	was	 applied	 for	 13	minutes	with	 a	 current	strength	of	1	mA.	Immediately	after	tDCS,	MEPs	were	recorded	up	to	2	hours	and	additionally	at	the	same	evening	(SE),	the	next	morning	(NM),	next	afternoon	(NA)	and	next	evening	(NE).		
 
Time	Course	
24		
	
2.6	Data	analysis	and	statistics			The	individual	MEP	amplitude	means	of	baselines	1,	2,	3	and	the	post-stimulation	time	points	were	calculated.	Post-stimulation	MEP	amplitudes	were	normalized	to	baseline	2	or	to	baseline	3	if	TMS	intensity	had	to	be	adjusted.	The	grand	averages	for	each	time	point	 per	 session	 were	 calculated	 by	 pooling	 the	 respective	 normalized	 MEP	amplitudes.	 A	 repeated	measure	 analysis	 of	 variance	 (ANOVA)	 was	 performed	 using	MEP	amplitude	as	 the	dependent	variable	and	medication	and	 time	course	as	within-subject	 factors.	 The	 Mauchly	 test	 of	 sphericity	 was	 performed,	 and	 the	 Greenhouse-Geisser	 correction	 was	 applied	 when	 necessary.	 In	 case	 of	 significant	 results	 of	 the	ANOVA,	 exploratory	 post	 hoc	 comparisons	 were	 performed	 using	 Student’s	 t-tests	(paired	samples,	two-tailed,	p	<	0.05,	not	corrected	for	multiple	comparisons)	between	the	MEP	amplitudes	before	and	after	 intervention	within	one	experimental	 condition,	and	 between	 intervention	 conditions	 (medication	 vs.	 placebo)	 within	 the	 same	 time	points.	To	 check	 for	 drug	 influence	 on	 cortical	 excitability,	 first,	 second,	 and	 third	 baseline	values	of	 the	same	conditions	were	compared	using	Student’s	 t-tests	 (paired	samples,	two-tailed,	p	<	0.05,	not	corrected	for	multiple	comparisons).		To	exclude	differences	between	baseline	values	of	different	 conditions,	 the	 respective	values	were	also	compared	using	Student’s	t-tests	(paired	samples,	two-tailed,	p	<	0.05,	not	corrected	for	multiple	comparisons).		Additionally,	 we	 used	 a	 one-way-ANOVA	 on	 MEP	 amplitudes	 pooled	 for	 the	 first	 30	minutes	after	plasticity	induction	and	normalized	to	baseline	2	(or	3,	if	applicable)	and	Student’s	 t-tests	 (paired	 samples,	 two-tailed,	 p	 <	 0.05,	 not	 corrected	 for	 multiple	comparisons)	 to	 compare	 the	 first	 30	minutes	 average	MEP	 amplitudes	 between	 real	substance	 exposition	 and	 respective	 placebo	 medication	 conditions.	
25		
	
3.	Results	
3.1	Side	effects			With	regard	to	side	effects,	after	administration	of	0.1	mg	of	apomorphine,	5	out	of	12	subjects	 experienced	 tiredness,	 one	 subject	 felt	 slight	 nausea,	 one	 experienced	 a	 dry	mouth	and	throat,	and	one	subject	complained	about	itchiness.	After	administrating	the	medium	dose	(0.2	mg	apomorphine),	8	out	of	the	12	subjects	experienced	fatigue,	one	subject	 reported	 a	 dry	mouth	 and	 sweating,	 4	 participants	 felt	 nausea	 and	 1	 subject	vomited.	After	administration	of	the	highest	dose	(0.3	mg	apomorphine),	8	out	of	the	12	subjects	experienced	tiredness,	1	hypotension,	5	felt	nausea	and	reported	an	increase	in	salivation.	 	Two	of	these	five	participants	vomited.	All	symptoms	were	fully	reversible	and	lasted	for	about	15	to	45	minutes.	No	subject	experienced	any	side	effect	from	TMS.	From	tDCS,	however,	participants	reported	mild	itching	and	burning	sensations	for	the	first	minute	of	stimulation.	
3.2	Control	analysis	of	baseline-measures				The	 average	 baseline	 MEP	 values	 did	 not	 significantly	 differ	 between	 medication	conditions,	 as	 confirmed	 by	 Student’s	 t-tests	 (paired	 samples,	 two	 tailed,	 p	 >	 0.05).	Furthermore,	apomorphine	alone	did	not	have	any	impact	on	cortical	excitability	at	any	dosage,	 which	 is	 confirmed	 by	 Student’s	 t-tests	 between	 first	 and	 second	 baseline	values	(paired	samples,	two-tailed,	p	>	0.05)	(Table	1).		a)	
							
Medication	
condition	
Baseline	1	 Baseline	2	 Baseline	3	 p-value	
BL	1vs	2	
p-value	
BL	1vs	3	Placebo	0.1	mg	 0.97	±	0.12	1.00	±	0.11	0.99	±	0.10	0.97	±	0.10	
0.94	±	0.21	1.03	±	0.28	0.87	±	0.26	0.88	±	0.54	
0.96	±	0.14	1.03	±	0.11	1.01	±	0.13	0.98	±	0.09	
0.612	0.666	0.148	0.574	
0.743	0.42	0.458	0.639	0.2	mg	0.3	mg	
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b)	 	
	
		
Table	1:	Descriptive	Statistics	of	a)	Baseline	MEPs	and	b)	Stimulation	intensity	The	means	of	the	baseline	MEPs	and	standard	deviations	are	shown	for	baseline	1,	2	and	3.	They	did	not	significantly	differ	across	medication	conditions,	as	tested	with	Student’s	t-tests.	Stimulation	intensity,	as	measured	 by	 percentage	 of	 maximum	 stimulator	 output	 (%MSO),	 mean	 and	 standard	 deviation	 for	baseline	1	and	2	accordingly	and	baseline	3	are	shown.	 	Student’s	 t-	 tests	 show	that	 these	also	did	not	differ	across	medication	conditions.		
	
3.3	Effect	of	apomorphine	on	anodal	tDCS-induced	plasticity		MEPs	in	the	placebo	medication	condition	were	significantly	enhanced	for	30	minutes	after	 anodal	 tDCS.	 After	 administration	 of	 apomorphine,	 MEP	 values	 did	 not	significantly	differ	from	baseline	values,	except	in	minute	0	where	excitatory	plasticity	was	 significantly	 reduced	 (Figure	 2).	 This	 suggests	 that	 anodal	 tDCS-induced	 after-effects	were	abolished	or	reduced	by	all	doses	of	apomorphine.			
	
Figure	6.	Time	course	of	the	MEP	values	after	tDCS	stimulation	
Medication	
condition	 Baseline	1/2	 Baseline	3	 p-value	BL	1/2	vs.	3	Placebo	0.1	mg	 48.92	±	10.35	48.75	±	8.95	48.17	±	9.13	47.08	±	7.61	
49.00	±	10.20	49.42	±	9.12	49.25	±	9.50	47.75	±	7.52	
0.071	0.674	0.151	0.255	0.2	mg	0.3	mg	
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The	x-axis	displays	the	time	points	in	minutes	after	anodal	tDCS.	The	y-axis	shows	the	MEP	amplitudes,	which	were	standardized	to	the	corresponding	baseline	values.	Error	bars	indicate	standard	error	of	the	mean	(SEM).	The	graph	illustrates	that	anodal	tDCS	induces	an	excitability	increase	lasting	for	about	30	minutes.	Low	dose	 (0.1	mg),	medium	dose	 (0.2	mg)	and	high	dose	 (0.3	mg)	of	apomorphine	 impaired	and	 abolished	 the	 after	 effects	 of	 anodal	 tDCS.	 After	 60	 minutes	 there	 were	 no	 significant	 effects	anymore.	 The	 filled	 symbols	 indicate	 statistically	 significant	 deviations	 of	 the	 post-tDCS	 MEP	 values	compared	 with	 baseline.	 The	 asterisks	 indicate	 significant	 differences	 between	 *	 placebo	 vs.	 0.1,	 #	placebo	vs.	0.2,	‡	placebo	vs.	0.3.	 	A	repeated	measures	analysis	of	variance		(RM	ANOVA)	was	calculated	with	the	factors	medication	condition	(4	levels:	placebo,	0.1	mg	apomorphine,	0.2	mg	apomorphine,	0.3	mg	apomorphine	)	and	time	(15	levels:	0	min,	5	min,	10	min,	15	min,	20	min,	25	min,	30	min,	 60	min,	 90	min,	 120	min,	 same	 evening,	 next	morning,	 next	 noon,	 next	 evening	after	tDCS).	The	RM	ANOVA	confirmed	a	significant	interaction	of	medication	condition	x	time	(F(42)=	2.035;	p<0.001)(table	2).			
Source df F Sig. 
Medication  
Condition 
3 1.309 .288 
Time 14 .429 .963 
Medication 
Condition x 
Time 
42 2.035 <.0001 
Table	2:	RM	ANOVA	of	medication	condition,	time	and	medication	condition	x	time	This	 table	 shows	 degrees	 of	 freedom	 (dF),	 F-statistics	 (F)	 and	 p-values	 (Sig.)	 of	medication	 condition,	Time	 and	 Medication	 Condition	 x	 Time.	 The	 main	 effects	 of	 medication	 condition	 and	 time	 were	 not	significant.	However,	there	is	a	significant	interaction	between	medication	condition	x	time.		
 
 Post-hoc	Student’s	 t-tests	showed	 that	MEP	amplitudes	 in	 the	placebo	condition	were	significantly	larger	than	baseline	between	0	–	15	min	and	30	minutes	after	anodal	tDCS	(p	<	0.05).	Furthermore	under	medium	and	high	dose	apomorphine	MEPs	were	reduced	significantly	 immediately	after	 stimulation	 (p=0.0001	and	p=0.002	 respectively).	 	The	remaining	 MEP	 amplitudes	 under	 low,	 medium	 and	 high	 dose	 apomorphine	 did	 not	significantly	differ	from	baseline	values	at	any	time	point	(p>0.05).			 For	the	effects	of	different	dosages	of	apomorphine	on	anodal	tDCS-induced	
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plasticity	with	regard	to	the	grand	average	calculated	for	the	first	30	min	after	intervention,	the	one-way	ANOVA	followed	by	exploratory	Students	t-test	revealed	differences	between	all	drug	and	the	respective	placebo	conditions:	all	doses	of	apomorphine	had	a	similar	abolishing	effect	on	anodal	tDCS-induced	facilitatory	plasticity,	which	was	significant	for	small	and	medium	dosages	(p=0.009,	p=0.001	and	p=0.151	for	0.1	mg,	0.2	mg	and	0.3	mg	vs.	placebo	respectively).			
 	 	
	
Figure	7.	Bar	charts	of	average	normalized	MEP	of	30	min	after	tDCS	Anodal	 tDCS	 alone	 (placebo	medication	 condition)	 leads	 to	 a	 significant	 increase	 of	MEP,	 anodal	 tDCS	combined	with	all	dosages	of	apomorphine	show	a	decrease	of	pooled	MEP	values,	which	is	significant	(p	<	 0.05)	 in	 comparison	 to	 the	 placebo	medication	 condition	 for	 small	 and	medium	 dosages.	 Error	 bars	indicate	SEM.	*	=	p	<	0.05					
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4.	Discussion		In	 this	experiment,	anodal	 tDCS	under	placebo	medication	 induced	LTP-like	plasticity,	which	was,	however,	abolished	by	apomorphine	independent	from	dosage.		
 
4.1	Anodal	tDCS	combined	with	placebo	medication		In	 the	 placebo	 medication	 condition,	 anodal	 tDCS	 over	 the	 primary	 motor	 cortex	induced	a	significant	increase	in	cortico-spinal	excitability.	These	after-effects	lasted	for	about	 30	 minutes	 in	 accordance	 with	 foregoing	 studies	 (Nitsche	 and	 Paulus	 2000;	Nitsche	and	Paulus	2001;	Nitsche	et	al.	2008).		
	 	
4.2.	Anodal	tDCS	with	apomorphine	condition		
 Increasing	 dopamine	 receptor	 activation	 by	 apomorphine	 abolished	 the	 excitability	enhancement	elicited	by	anodal	tDCS	in	this	study	with	all	dosages	applied.		0.1	mg,	0.2	mg	and	0.3	mg	of	 apomorphine	are	all	 equivalent	 to	 low	dosage	of	other	dopamine	agonists,	because	in	Parkinsonian	patients	it	has	been	postulated	that	for	diagnostic	testing	1.5	–	4.5	mg	apomorphine	is	equal	to	a	dosage	of	250	mg	L-dopa	(Koller	and	Stacy	2004).	Hence	0.1	–	0.3	mg	apomorphine	can	be	compared	roughly	to	25	mg	L-dopa.		Consequently,	the	result	from	the	current	study	is	in	line	with	previous	research	that	 showed	 that	 a	 low	 dose	 of	 L-dopa	 abolishes	 facilitatory	 as	 well	 as	 inhibitory	plasticity,	where	25	mg	of	L-dopa	abolished	after-effects	of	 tDCS	and	diminished	PAS-induced	 excitability	 changes	 (Monte-Silva	 et	 al.	 2010;	 Thirugnanasambandam	 et	 al.	2011).		
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Stimulating	D1,	D2	or	D2/	D3	receptors	with	low	dose	dopamine	agonists,	which	have	 been	 related	 to	 25	 mg	 low	 dose	 L-dopa,	 also	 reduces	 tDCS-induced	 plasticity	(Monte-Silva	et	al.	2009;	Fresnoza	et	al.	2014a;	Fresnoza	et	al.	2014b).	For	instance	low	doses	 of	 ropinirole,	 a	 D2/D3	 dopamine	 agonist,	 impair	 tDCS-	 and	 PAS-induced	 after-effects	(Monte-Silva	et	al.	2009)	as	do	low	doses	of	bromocriptine,	a	selective	D2	agonist	(Fresnoza	 et	 al.	 2014a).	 For	 predominant	 D1	 receptor	 activation	 by	 block	 of	 D2	receptors	during	 simultaneous	 application	of	 L-dopa,	 Fresnoza	 et	 al.	 (2014b)	 showed	also	that	anodal	tDCS-induced	plasticity	is	impaired	under	low	dosage.		Not	 only	 compared	 to	 L-dopa	 and	 other	 dopaminergic	 substances,	 the	apomorphine	dosages	applied	in	the	present	study	are	equivalent	to	low	doses,	but	also	when	compared	to	the	range	of	apomorphine	dosages.	Even	the	highest	dose	of	0.3	mg	is	quite	low	when	compared	to	4	mg,	the	average	dose	for	Parkinson	patients	during	a	hypokinetic	period	(Stacy	2004).	Since	Parkinsonian	patients	have	a	lack	of	dopamine	it	is	 not	 appropriate	 to	 compare	 their	 dosage	 to	 healthy	 participants	 without	dopaminergic	 deficits.	 Nevertheless,	 also	 comparing	 the	 dosages	 to	 other	 studies	 it	becomes	 clear	 that	 these	 are	 low	 doses.	 Examining	 the	 effect	 of	 apomorphine	 on	cognition,	0.005	mg/kg	was	used	as	a	low	dose,	which	would	equal	to	0.3	mg	in	a	60	kg	person,	which	was	the	highest	dose	used	in	our	study	(Friston	et	al.	1992;	Montoya	et	al.	2008).		Although	apomorphine	 is	a	global	dopamine	receptor	agonist,	 it	 is	 thought	that	low	doses	of	apomorphine	(i.e.,	~0.004	mg/kg)	mainly	stimulate	presynaptic	dopamine	receptors	(Di	Chiara	et	al.	1976;	Yamada	and	Furukawa	1980;	LeWitt	2004;	Montoya	et	al.	2008;	Schellekens	et	al.	2010;	Passamonti	et	al.	2013).	 	Presynaptic	receptors	serve	as	autoreceptors,	which	are	regulatory	receptors	that	modulate	membrane	excitability	and	 influence	the	synthesis	and	metabolism	of	dopamine,	hence	controlling	dopamine	
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release	 and	 reuptake	 (Schmitz	 et	 al.	 2003).	 They	 belong	 to	 the	 D2	 family,	 which	 is	coupled	 with	 inhibitory	 G-proteins,	 therefore	 suppressing	 adenyl	 cyclase	 and	 thus	inhibiting	dopaminergic	neurons	(Wolf	and	Roth	1990;	Usiello	et	al.	2000;	Centonze	et	al.	 2003).	 Consequently,	 by	 binding	 at	 presynaptic	 receptors,	 dopamine	 activates	 a	negative	 feedback	 mechanism,	 in	 which	 the	 presynapse	 is	 hyperpolarized	 and	 less	dopamine	 is	 synthesized	 and	 released	 (Benoit-Marand	 et	 al.	 2001).	 Hence	 the	extracellular	dopamine	concentration	is	reduced	and	the	firing	rate	of	the	dopaminergic	neurons	is	decreased	(Schmitz	et	al.	2003).	In	line	with	this,	it	has	been	shown	that	D2-like	 autoreceptor	 activation	 by	 pergolide	 might	 cause	 impaired	 learning	 in	 humans	(Breitenstein	et	 al.	 2006).	This	activation	of	dopaminergic	autoreceptors	by	 relatively	low-dose	apomorphine	is	therefore	a	possible	explanation	for	the	results	of	the	present	study.	 Animal	 studies	 support	 this	 hypothesis,	 as	 it	 was	 also	 shown	 in	 rats	 that	 low	doses	 of	 apomorphine	 preferentially	 activate	 D2	 autoreceptors	 and	 inhibit	dopaminergic	 neurons,	 thus	 suppressing	 locomotor	 behavior;	 whereas	 higher	 doses	activate	post-synaptic	receptors	and	have	an	enhancing	effect	on	memory	consolidation	(Carrera	et	al.	2011).	Human	cognition	studies	show	a	similar	effect.	Administration	of	0.005	 mg/kg	 apomorphine	 s.c.	 decreased	 cognitive	 performance	 in	 healthy	 subjects	(Schellekens	 et	 al.	 2009;	 Schellekens	 et	 al.	 2010).	 The	 authors	 suggested	 that	apomorphine	leads	to	activation	of	presynaptic	dopamine	receptors	and	subsequently	a	decrease	in	dopamine	neurotransmission,	as	the	effect	was	more	severe	in	participants	with	 poor	 baseline	 performance,	 presumably	 due	 to	 a	 lower	 level	 of	 prefrontal	dopamine	 functioning.	However,	one	has	 to	state	 that	 this	explanation	of	our	result	 is	speculative	at	present.	 	As	 explained	 in	 the	 introduction,	 tDCS-induced	 plasticity	 depends	 on	 NMDA	receptors	and	thus	glutmatergic	synapses	as	well	as	reduction	of	GABAergic	activity	and	
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that	 they	 are	 calcium	 channel	 dependent	 (Nitsche	 et	 al.	 2003b;	 Nitsche	 et	 al.	 2004;	Fritsch	et	al.	2010;	Stagg	et	al.	2011).	Consequently	 it	 is	 likely,	albeit	speculative,	 that	those	systems	are	relevant	for	the	results	of	the	present	study.		In	accordance	with	this	hypothesis,	 Momiyama	 (et	 al.	 1996)	 have	 shown	 that	 activation	 of	 presynaptic	dopamine	 receptors	 reduce	 excitatory	 glutamatergic	 transmission,	 which	 might	 be	mediated	through	a	cAMP-dependent	pathway	resulting	in	a	reduction	of	calcium	influx	into	 the	 glutamatergic	 synapse	 (Momiyama	 et	 al.	 1996).	 Nitsche	 et	 al.	 (2003b)	 have	shown	 the	 calcium	 dependence	 of	 tDCS.	 Since	 formation	 of	 LTP	 is	 prevented	 if	 the	intracellular	calcium	concentration	is	too	low	(Lisman	2001),	it	can	be	argued	that	low	dosages	of	apomorphine	activate	autoreceptors	that	through	different	pathways	lead	to	a	reduction	of	calcium	influx	and	thus	LTP	formation	(Momiyama	et	al.	1996).			 Some	potential	limitations	of	this	study	should	be	considered.	Firstly,	the	results	of	 apomorphine	 effects	 on	 cathodal	 tDCS	 as	 well	 as	 PAS-induced	 focal	 plasticity	 are	lacking	a	more	complete	picture	of	the	effects	of	apomorphine	on	human	motor	cortex	plasticity.	Respective	experiments	are	still	ongoing.		Secondly,	 CNS	 active	 drugs	 such	 as	 apomorphine	 can	 alter	 attention	 and	vigilance	and	thus	contribute	to	the	observed	drug	effects	on	TMS	measures	(Ziemann	et	al.	2015).	Since	apomorphine	induced	relevant	side	effects,	especially	tiredness	and	nausea,	the	plasticity	abolishing	effect	could	be	at	least	partially	explained	by	those	side	effects.	However,	to	control	for	a	drug	effect	on	attention	and	vigilance	we	measured	a	second	baseline	10	minutes	after	injecting	apomorphine.	At	this	time	the	plasma	level	of	apomorphine	 is	 maximal.	 	 The	 Student’s	 t-test	 comparing	 first,	 second	 and	 third	baseline	 values	 did	 not	 show	 significant	 excitability	 differences,	 thus	 suggesting	 that	apomorphine	alone	did	not	 influence	 cortical	 excitability	 at	 any	dosage.	 Furthermore,	
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other	studies	have	shown	that	 lorazepam,	which	as	well	causes	tiredness,	did	also	not	relevantly	alter	tDCS	effects	(Nitsche	et	al.	2004).		Thirdly,	 due	 to	 differences	 in	 body	 weight,	 as	 well	 as	 various	 genetic	polymorphisms	of	proteins	involved	in	regulating,	for	instance,	dopamine	transport	or	uptake,	 a	 significant	 inter-individual	 variability	 of	 the	 drug	 effects	 on	 blood	concentration	and	hence	cortical	plasticity	might	exist	 (Moreau	et	al.	2015;	Uno	et	al.	2015;	 Ziemann	 et	 al.	 2015).	 A	 limitation	 could	 be	 that	 blood	 concentration	 of	apomorphine	was	not	measured.	Fourthly,	 Wiethoff	 et	 al.	 (2014)	 have	 shown	 that	 even	 though	 anodal	 tDCS	facilitates	MEPs,	there	is	a	relevant	inter-individual	variability	in	the	response	to	tDCS.	However	 they	 used	 a	 stimulation	 intensity	 of	 2	 mA,	 whose	 effect	 differs	 from	 1	 mA	protocols	(Batsikadze	et	al.	2013).	Also,	anatomical	differences	might	account	for	inter-individual	variability	of	tDCS-induced	plasticity	(Datta	et	al.	2012).	Despite	those	inter-individual	 differences,	 we	 could,	 however,	 show	 that	 in	 the	 placebo	 medication	condition	anodal	tDCS	induces	a	significant	increase	in	motor	cortex	excitability.		The	 results	 of	 this	 study	 furthermore	 confirm	 the	 narrow	 range	 in	 which	dopamine	receptors	work	optimally	and	how	 important	 consideration	of	 this	 is	when	treating	 patients	with	 diseases	 affecting	 the	 dopaminergic	 system.	 	 Therefore	 further	research	 is	 very	 important	 to	 examine	 the	 influence	 of	 dopamine	 on	 neuroplasticity,	especially	apomorphine,	as	there	are	little	studies	so	far	using	this	substance.	It	would	be	of	great	interest	to	examine	the	influence	of	higher	doses	of	apomorphine	on	tDCS-	as	well	 as	 PAS-induced	 plasticity.	 	 Furthermore	 it	 would	 be	 interesting	 to	 examine	 the	effect	 of	 apomorphine	 on	 plasticity	 in	 Parkinsonian	 patients,	 as	 they	 are	 deprived	 of	dopamine	and	the	increase	of	it	might	have	a	different	effect	than	in	healthy	subjects.			 	
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5.	Summary			The	aim	of	this	thesis	was	to	study	the	effect	of	apomorphine	on	non-focal	anodal	tDCS-induced	plasticity	and	 thus	 further	examine	 the	 influence	of	 the	dopaminergic	system	on	motor	 cortex	plasticity	 in	 humans.	 In	 a	 randomized	double	 blind	 study	design,	 12	healthy	subjects	received	in	four	different	sessions	intracutaneous	injections	of	placebo	or	0.1,	0.2,	0.3	mg	of	apomorphine,	a	global	dopamine	agonist,	while	the	effect	of	anodal	tDCS-induced	 motor	 cortical	 plasticity	 was	 examined.	 In	 accordance	 with	 previous	research,	 in	 the	 placebo	 medication	 condition	 cortical	 excitability	 was	 significantly	enhanced	 by	 anodal	 tDCS.	 For	 all	 dosages	 of	 apomorphine	 explored	 in	 the	 present	experiment,	anodal	tDCS-induced	plasticity	effects	were	abolished.	0.1,	0.2,	and	0.3	mg	apomorphine	are	comparable	 to	 low	doses	of	other	dopamine	agents,	 such	as	L-dopa.	Hence,	 those	 findings	 are	 in	 line	 with	 previous	 research	 showing	 that	 low	 doses	 of	dopamine	lead	to	an	abolishment	of	plasticity	induction.	Low	doses	of	apomorphine	(i.e.	~0.004	 mg/kg)	 are	 assumed	 to	 mainly	 stimulate	 presynaptic	 dopamine	 receptors,	whose	activation	leads	to	a	decrease	in	dopamine	neurotransmission	through	negative	feedback	 mechanisms	 	 and	 thus	 to	 a	 reduction	 in	 dopaminergic	 firing	 rate.	 As	 the	activation	 of	 presynaptic	 dopamine	 receptors	 reduce	 excitatory	 glutamatergic	transmission,	this	can	explain	why	apomorphine	abolished	the	anodal	tDCS	effect.			However,	 some	 questions	 remain	 to	 be	 explored,	 for	 instance	 the	 influence	 of	higher	 doses	 of	 apomorphine	 on	 tDCS-induced	 plasticity	 and	 consequently	 more	research	is	needed	to	fully	understand	the	role	of	dopamine	in	neuroplasticity.			 	
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